| Literature DB >> 35587154 |
Shuai Kong1, Shubo Tian1, Zhu Wang1, Yulong Shi1, Jizhun Zhang1, Hongqing Zhuo1.
Abstract
The treatment of gastric cancer (GC) is extremely challenging; however, the specific pathogenesis of GC remains unclear. Circular RNAs (CircRNAs) are non-coding RNAs that can regulate gene expression both transcriptionally and post-transcriptionally. However, little is known about the circRNAs that are important in the progression of GC. This study identified significantly dysregulated circRNAs by analyzing gastric cancer patients and normal control tissues. The target gene was predicted using online bioinformatics tools and verified using RNA pull-down and luciferase reporter assays. Quantitative real-time polymerase chain reaction (qRT-PCR) and western blotting were used to evaluate gene and protein expression. The malignant behavior of GC cells was determined using 3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyl tetrazolium bromide (MTT) assay, wound healing assay, Transwell invasion assay, and flow cytometry. CircPFKP is downregulated in GC tissues, and overexpression of circPFKP inhibits malignant behavior in GC cells. Bioinformatics predicted that circPFKP could bind to miR-644, and miR-644 could target disintegrin-like and metalloprotease domain-containing thrombospondin type 1 motif-like 5 (ADAMTSL5). Overexpression of circPFKP enhances the expression of ADAMTSL5 by decreasing the expression of miR-644 to suppress the growth of xenograft GC tumors in vivo and in vitro. In conclusion, the circPFKP/miR-644/ADAMTSL5 regulatory pathway inhibited the malignant progression of GC. These findings may extend our understanding of the effects of circRNAs on cancer development and provide novel targets for the diagnosis of GC.Entities:
Keywords: ADAMTSL5; cell cycle; circPFKP; gastric cancer; miR-644
Mesh:
Substances:
Year: 2022 PMID: 35587154 PMCID: PMC9275984 DOI: 10.1080/21655979.2022.2073001
Source DB: PubMed Journal: Bioengineered ISSN: 2165-5979 Impact factor: 6.832
Figure 1.circPFKP was lowly expressed in gastric cancer.
Figure 2.The identification of circPFKP in the gastric cancer cells.
Figure 3.circPFKP inhibited the progression of gastric cancer.
Figure 4.circPFKP sponges miR-644 in gastric cancer cells.
Figure 5.miR-644 targets ADAMTSL5 in gastric cancer cells.
Figure 6.Inhibition of miR-644 or ADAMTSL5 overexpression reversed the effect of circPFKP silencing.
Figure 7.circPFKP promotes tumor proliferation and metastasis.